A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Trial details
- Registry ID
- NCT05744401
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseNCT05744401 | ALEC | Phase 2 | Terminated | 2025-01-31Actual |
| A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 | ALEC | Phase 2 | Completed | 2024-08-19Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |